Diagnostic Efficacy of Computed Tomography in Detecting Cervical Metastases in Clinically N0 Head and Neck Squamous Cell Carcinoma

Effect of Nano-Tracer on Identification of Sentinel Lymph Nodes in Pelvic Cavity and Postoperative Complications in Patients with Cervical Cancer

Cervical cancer is the most common malignant tumor of the female reproductive system. Its incidence rate ranks first among female malignant tumors in China and has been increasing in recent years. However, pelvic lymph node metastasis is an important factor affecting the prognosis of cervical cancer, because pelvic lymph node metastasis determines the scope of surgery, it is also an important basis for postoperative adjuvant treatment. Therefore, an accurate and effective method is needed to detect the presence of lymphatic metastases in time to guide the need for systematic pelvic lymph node dissection. This article explores the clinical application of nano-tracer in the surgical treatment of cervical cancer patients and the impact of postoperative complications on patients with pelvic sentinel lymph nodes. The results show that the success rate of sentinel lymph node tracing in cervical cancer surgery is high, and it is a safe and efficient lymph tracer, which can provide an effective way to study cervical micro metastasis and lymphatic chemotherapy.

Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma

OBJECTIVE

Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab.

METHODS

We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions.

RESULTS

In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: -10.0% vs. 23.1%, p = 0.033).

CONCLUSION

PTS may impact the response to nivolumab in HNSCC patients.